Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 4/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365639 | 0.91 | PIM2 (0.38) | PIM2PIM3FAAHPIM1ATR | |
| SCHEMBL17618730 | 0.88 | LRRK2 (0.36) | PIM2PIM3FAAHPIM1RPS6KB1 | |
| SCHEMBL19365551 | 0.87 | PIM2 (0.34) | PIM2PIM3FAAHROCK2ROCK1 | |
| SCHEMBL17618675 | 0.86 | PIM3 (0.46) | PIM2PIM3FAAHROCK2ROCK1 | |
| SCHEMBL17618755 | 0.86 | GSK3B (0.38) | PIM2PIM3ROCK2ROCK1CYP11B2 | |
| SCHEMBL17618619 | 0.86 | PIM2 (0.37) | PIM2PIM3PIM1 | |
| SCHEMBL17618610 | 0.85 | PIK3C3 (0.38) | PIM2PIM3FAAHPIM1ATR | |
| SCHEMBL19365349 | 0.84 | CDK9 (0.35) | PIM2PIM3 | |
| SCHEMBL17618526 | 0.83 | FAAH (0.35) | FAAHRPS6KB1ATR | |
| SCHEMBL17618692 | 0.83 | PIM2 (0.36) | PIM2PIM3FAAHROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIM2 3242/4885PIM3 3489/4885FAAH 977/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PIM2 3242/4885PIM3 3489/4885FAAH 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.